November 10, 2025 a 08:39 am
PODD: Analysts Ratings - Insulet Corporation
Insulet Corporation, with its innovative insulin delivery solutions, continues to experience stable interest from analysts. As we approach the end of 2025, the stock maintains a robust buy-side sentiment, reflecting confidence in its market position. The analyst ratings suggest a favorable outlook despite minor fluctuations in overall sentiment in recent months.
Historical Stock Grades
The latest analyst ratings from November 2025 indicate a strong positive sentiment towards PODD, with 22 analysts recommending a buy or strong buy. This momentum is bolstered by no strong sell or sell recommendations, indicating confidence in the company's growth trajectory.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 17 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the past months, the sentiment surrounding PODD has shown stability, with a predominance of "Buy" ratings. Although the number of "Strong Buy" ratings saw a slight decline, the overall buoyant sentiment has persisted.
- From May to November 2025, "Buy" recommendations consistently remained high at around 14-17.
- "Strong Buy" ratings showed minor fluctuations, decreasing from 7 in May to 5 in November 2025.
- The "Hold" category saw modest changes, indicating a balanced view among analysts.
Percentage Trends
Throughout 2025, there has been a notable shift in the distribution of ratings. The proportion of "Buy" ratings consistently accounted for over 60%, signaling robust market confidence. A minor uptick in "Hold" ratings suggests a cautious optimism, while the absence of "Sell" ratings mirrors strong market reassurance.
- In June 2025, "Strong Buy" represented 23% of recommendations, slightly decreasing to 19% in November 2025.
- "Buy" ratings maintained a dominant share, steadily contributing to over 60% throughout the year.
- The "Hold" category increased slightly, reflecting cautiousness against a backdrop of consistent performance.
Latest Analyst Recommendations
Recent analyst recommendations for PODD continue to reflect a positive sentiment. The stability in recommendations highlights sustained confidence in the stock's trajectory and valuation.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-07 | Overweight | Overweight | Wells Fargo |
| 2025-11-07 | Neutral | Neutral | UBS |
| 2025-11-07 | Outperform | Outperform | RBC Capital |
| 2025-11-07 | Buy | Buy | Canaccord Genuity |
| 2025-11-07 | Buy | Buy | Truist Securities |
Analyst Recommendations with Change of Opinion
The table below highlights recent shifts in analyst opinions about PODD stock. Notably, these changes reflect both upward and downward adjustments, offering insight into nuanced market perspectives and strategic repositioning.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-13 | Outperform | Peer Perform | Wolfe Research |
| 2025-04-29 | Peer Perform | Outperform | Wolfe Research |
| 2024-06-10 | Mixed | Positive | OTR Global |
| 2024-05-07 | Outperform | Peer Perform | Wolfe Research |
| 2023-12-21 | Outperform | Neutral | Baird |
Interpretation
The continuous buy-side dominance with negligible sell-side activity underscores confidence in Insulet Corporation's strategic positioning. Despite minor fluctuations in ratings, the analyst sentiment illustrates a stable agreement on the stock's potential and growth prospects. These consistent ratings signal resilience amid market dynamics and reflect an overall reliable market confidence towards PODD.
Conclusion
Insulet Corporation's stock demonstrates a promising outlook, buoyed by a majority of buy recommendations over the past year. While some ratings shifts hint at cautiousness, the lack of sell recommendations speaks to enduring strength. Analysts appear to remain positive, indicating a favorable investment proposition and predicting steady growth within the market. Maintaining performance in a competitive landscape, Insulet's innovations continue to be well-regarded, making it a solid choice for investors seeking stability in the healthcare sector.